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Chloroquine (CQ); a lysosomotropic agent used for decade ago as anti-malarial, was tested against aging induced
osteoporosis. Osteoporosis in male rats was induced using D-galactose (D-gal) as a reducing sugar at a dose of 200
mg/kg/day; i.p. Osteoporotic rats were orally treated with CQ (10 mg/kg/day) for four successive weeks. Bone
densitometry of tibia and femur were evaluated. Bone formation biomarkers; osteoprotegrin (OPG), bone specific
alkaline phosphatse (BALP), and osteocalcin (OCN), and bone resorption biomarker; receptor activator of nuclear
factor kappa-B ligand (RANKL), cathepsin-k (CTSK), tartrate-resistant acid phosphatase (TRAP) were estimated.
Moreover, the expression of extracellular regulated kinase (ERK) in bone was determined. CQ ameliorated the
bone detrimental changes induced by D-galactose. It enhanced bone health as revealed by measurement of bone
densitometry, halted the activation of receptor activator of nuclear factor kappa-B ligand (RANKL) and reduced
bone manifestation of ERK. Furthermore, CQ treatment abated serum cathepsin-k (CTSK) and serum tartrateresistant acid phosphatase (TRAP) thus inhibited osteoclastogenesis and consequently restored the RANKL/
OPG ratio. CQ demonstrated an antioxidant effect in bone where it increased both Catalase (CAT) and Super
oxide dismutase (SOD). These CQ preserving effect in rats treated with D-galactose were confirmed by the his
topathological examination. The present study points to the potential therapeutic effect of CQ as antiosteoporotic agent possibly through its antioxidant effects and suppression of ERK associated osteoclastogenesis.
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1. Introduction
Osteoporosis is signalized by decrease in bone mass ensuing from the
disproportion among bone resorption and bone formation rate which
enhances bone fragility and subsequently increases fracture risk [1].
When the bone resorption cells predominate, bone turnover takes place
in both genders at the tissue levels which impairs osteoblastic bone
formation and causes bone loss particularly during aging [2].
Free radical and oxidative stress subsequently produced from the
excessive formation of reactive oxygen species (ROS) are the most
promising reasons for the process of aging, inflammatory arthritis, and
age-related bone loss [3]. Mitochondrial ROS as hydrogen peroxide and
superoxide are metabolic by-products produced by complex I in electron
transport chain [4,5]. NADPH oxidase (NOX) contributes to the pro
duction of ROS through oxidation of the intracellular NADPH to NADP+
and donating electrons through membranes which reduced the

molecular oxygen and engendered superoxide anions [6]. Failure to
maintain healthy mitochondria could result in overproduction of ROS
and successively leads to chronic diseases such as osteoporosis [7].
Moreover, a former study [8] showed that, SOD regulates the osteoblast
activity and hence osteoclastogenesis through RANKL signaling.
Antioxidants act as a defense mechanism against the reactive species
derived from oxygen and nitrogen by reducing the oxidative damage to
the tissues [9]. Superoxide dismutase (SOD) and catalase (CAT) both
have significant roles as antioxidants. SOD reduces the superoxide
radicle to hydrogen peroxide and molecular oxygen while CAT converts
the hydrogen peroxide into water [10]. However, accumulation of ROS
decreases the activity of the antioxidant enzymes which subsequently
lead to oxidative stress [11,12] by disturbing the balance between the
oxidant and the antioxidants [13]. It also induces mitochondrial mal
function and lipid peroxidation which result in further increase of ROS
production and osteoclasts differentiation through upregulation of the
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receptor activator of nuclear factor-κβ ligand RANKL [14,15]. Activation
of RANKL/RANK signaling has an important role in bone turnover which
could be prevented by the expression of the decoy receptor osteopro
tegrin (OPG) on osteoblastic cells which protects against bone turnover
[16]. ROS modulated the mitogen-activated protein kinase; extracel
lular regulated kinase (ERK) pathway to induce expression of RANKL in
osteoblasts [17–19] which in-turn altered the ratio of receptor activator
of nuclear factor kappa-B ligand and osteoprotegrin (RANKL/OPG) and
subsequently enhanced the conversion to bone-catabolizing osteoclastic
cells [20]. Activation of osteoclasts (OCs) by ROS also causes the
expression of tartrate-resistant acid phosphatase (TRAP) and
cathepsin-k (CTSK) that are important to osteoclastogenesis. They both
have an essential role in bone remodeling as they are found abundantly
in the ruffled borders of osteoclastic cells and cause degradation and
demineralization of bone matrix especially type-1 collagen which con
tributes to bone loss [21]. Moreover, excessive formation of ROS leads to
the production of autophagy which is a highly conserved intracellular
catabolic process that maintains cellular homeostasis through which the
damaged cellular components are degraded for the production of energy
[22]. However, a previous study by Shi et al. [23] revealed a significant
upregulation in autophagic activity followed by OCs differentiation
during oxidative stress.
Chloroquine (CQ) is approved for the treatment of uncomplicated
malaria due to susceptible plasmodium strains [24]. It may be used for
musculoskeletal inflammatory disease rheumatoid arthritis as well as for
treating discoid and systemic lupus erythematosus [25]. Due to its
alkaline properties, CQ is highly lipid soluble and can neutralize the
acidic compartments of the cell as endosomes and lysosomes [26].
Several reports showed that CQ and its derivative hydroxychloroquine
prevent vascular damage by inhibiting angiogenesis in discoid lupus
erythematosus [27]. Moreover, CQ has been used to control influenza
virus type A and type B as well as inhibiting the multiplication of H1N1
and avian viruses [28]. A former study showed that it also prevents
expression of inflammatory mediators by blocking autophagic flux
through inhibition of autolysosomes formation [29]. Moreover, a pre
vious study demonstrated CQ interference with ERK activation in-vitro
is related to its inflammatory effect [30].
The present study was carried out to investigate the possible repur
posing of CQ to bone health. CQ was investigated in D-galactose (D-gal)
induced osteoporosis in male rats through its impact on the activation of
ERK/RANKL pathway. Furthermore, CQ effect on antioxidant enzymes
was examined together with its subsequent influence on the inhibition of
TRAP and CTSK during osteoclastogenesis. Osteoporosis was monitored

through dual energy X-ray absorptiometry and histopathological
examination.
2. Material and methods
2.1. Experimental animal
Thirty-six adult male Wistar albino rats (three months old) gauging
150− 180 g and were supplied from the animal house colony of the
National Research Center (Giza, Egypt). They were kept and housed in
proper environmental conditions all throughout the time of examina
tion; surrounding temperature (25 ± 2 ◦ C), moisture (60 ± 10 %), and
light-dark cycles every 12 h. Animals were fed on a standard rat pellet
diet (United Co. for poultry production, El-Obour city, Cairo, Egypt) and
indorsed free admittance to water. The investigational procedure of this
study was reliable with the National Institute of Health Guidelines (NIH
Publications No. 80-23; 1996). Furthermore, moral endorsement was
accommodated for the present study by the research Ethical Committee,
Faculty of Pharmacy, Cairo University, Cairo, Egypt (ethical approval
No. PT 1395; 2015).
2.2. Study design
After a 2 weeks acclimatization period, all animals were divided into
three groups each of 12 rats; Group 1: normal rats received equivalent
volume of saline act as a control group, Group 2: rats received D-gal
dosage of 200 mg/kg/day, i.p. for 8 consecutive weeks and served as
osteoporotic rats, Group 3: rats received D-gal dosage of 200 mg/kg/day,
i.p. for 8 consecutive weeks followed by CQ at a dose of 10 mg/kg/day
for 4 successive weeks. D-gal dosage of 200 mg/kg/day, i.p. for 8
consecutive weeks was based on a previous study [12,31]. Dosage of CQ
was selected based on the previous studies [32,33]. By the end of the
twelfth week, blood samples were gathered and kept frozen at − 70 ◦ C.
Femoral and tibia bone samples were then detached and washed off soft
tissues to be scanned for bone densitometry as illustrated in Fig. 1.
2.3. Determination of femoral and tibia bone densitometry using central
dual energy x-ray absorptiometry (DEXA)
Rats were forfeited; bone femur and tibia were removed, eviscerated,
and then placed under the scanner arm of a Norland XR-46 to perform a
DEXA scan. The device estimates bone mineral content (BMC) in grams
and area in cm2 through directing a flimsy imperceptible x-ray beam

Fig. 1. Schematic diagram showing the experimental design of the present study.
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through the bone. After scanning; the information is kept by the com
puter unit and used to analyze bone mineral density (BMD) in g/cm2 by
dividing BMC over area of bone measured. Fig. 2 shows the scanning of
bone tibia and femur.

protein were encumbered into each mini-gel well. The gel was then
collected in a transferal sandwich with PVDV membrane, located in an
allocation container (Bio-Rad Trans-Blot Turbo) with 1x transfer buffer
to permit protein bands movement from gel to membrane. In order to
completely block the membrane for 1 h, Tris-buffered saline which
comprises Tween 20 (TBST) and 3% bovine serum albumin (BSA) is used
at lukewarm that diluted the Primary ERK antibodies concentration
referring to the constructor’s guidelines. Incubation at 4 ◦ C was done
during night in the primary antibody solution alongside the marked
aimed protein. HRP-conjugated secondary antibody solution (goat antirabbit IgG- HRP-1 mg goat mAb -Novus Biologicals) was added to the
membrane and incubation takes place against the blotted target protein
for 1 h at ambient temperature. The chemiluminescent substrate
(Clarity™ Western ECL substrate Bio-Rad cat#170-5060) was appli
cable to the blot conferring to the constructor’s endorsement. Computer
program used to evaluate the images by interpreting the band intensity
of the marked proteins opposing the control tester beta actin; house
keeping protein on the ChemiDoc MP imager. The primary antibodies
against ERK (Cat # sc-1647), were purchased from Santa Cruz
Biotechnology, Inc. (Dallas, Texas, USA), and the secondary antibody
(goat anti-rabbit IgG; HRP-1 mg goat mAb) were purchased from Novus
Biologicals (Littleton, Colorado, USA).

2.4. Determination of serum calcium and phosphorus
The serum levels of calcium and phosphorus in blood were evaluated
colorimetrically (Bio-diagnostic, Cairo, Egypt) at 585 nm conferring to
the technique designated by [34] and at 640 nm relying on the process
defined by [35] respectively.
2.5. Determination of bone turnover biomarkers
The serum concentration of bone-specific alkaline phosphatase
(BALP), osteocalcin (OCN), and osteoprotegrin (OPG), receptor acti
vator of nuclear factor kappa beta ligand (RANKL), tartrate-resistant
acid phosphatase (TRAP), Cathepsin k (CTSK) were evaluated by sand
wich ELISA kit (Biotang Inc., Waltham, Massachusetts, USA).
2.6. Measurement of anti-oxidant enzymes
The oxidoreductases catalase (CAT) in U/L and superoxide dismutase
(SOD) in U/mL serum activity were valued using colorimetric kit (Biodiagnostic, Cairo, Egypt) at 510 nm agreeing to the procedure pro
nounced by [36] and at 560 nm conferring to the method pronounced by
[37].

2.8. Histopathological examination
The animals were sacrificed via pentobarbital overdose (100 mg/kg).
Then, tibia and femur bone were detached and preserved in 10 % neutral
buffered formalin for 48 h, and then were fixed in 10 % ethylene
diamine tetra-acetic acid (EDTA) for decalcification. Tissue handling
was done through graded ethanol, xylol, and paraffin for dehydration,
clearing, impregnation, and embedding. Histologic sections with a
thickness of 6 μm were arranged and afterword they were regularly
tainted with hematoxylin and eosin. A scoring scale was used to assess
osteoporosis according to [38]. The scoring was 1: <25 % bone showing
osteopenia, 1+: 25− 50 % bone showing osteopenia, 2+: 50− 75 % bone
showing osteopenia 3+: >75 % bone showing osteopenia.

2.7. Quantitative western blot of bone ERK Protein
The prepared samples of the scraped bone tissues were treated by the
ReadyPrep™ protein extraction kit provided by Bio-Rad Inc. (Catalog
#163-2086) according to the manufacturer constructions. Quantitative
measurements for protein assay were done by Bradford Protein Assay Kit
(Cat # SK3041, Bio Basic Inc., Ontario, Canada). Parting of the protein
samples due to the difference in their molecular weight was done on a
polyacrylamide gel in a regular running buffer after 20 μg of total

Fig. 2. Represents bone densitometry of tibia and femur scanned by NORLND XR-46. The scanning was performed with a speed of 60 mm/s and 1.0 × 1.0 mm
resolution with the same duration of time for each group. Control (A), D-galactose (B), and CQ (C).
368

M.A.A. Mahmoud et al.

Toxicology Reports 8 (2021) 366–375

Fig. 3. Effect of CQ on BMD in D-gal induced osteoporotic rats.
Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.p. for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with CQ
(10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, Tibia bone and Femur bone were scanned using a regional high-resolution scan of the right and left
femurs. Results are expressed as mean ± S.E.M. (n = 10–12). Data were statistically estimated using one-way ANOVA followed by Tukey’s multiple comparisons test.
Variances were deemed statistically significant when *p < 0.05 in contrast to the control group and @ p < 0.05 in contrast to D-gal treated group.

Fig. 4. Effect of CQ on bone minerals in D-gal induced osteoporotic rats.
Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.p. for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with CQ
(10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, serum Ca+2 and serum P were determined using UV–vis spectrophotometer. Results are expressed as
mean ± S.E.M. (n = 10–12). Data were statistically estimated using one-way ANOVA followed by Tukey’s multiple comparisons test. Variances were deemed sta
tistically significant when *p < 0.05 in contrast to the control group and @ p < 0.05 in contrast to D-gal treated group.

Fig. 5. Effect of CQ on antioxidants biomarkers in D-gal induced osteoporotic rats. Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.p.
for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with CQ (10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, serum su
peroxide dismutase (a) and serum catalase (b) were established using UV–vis spectrophotometer. Results are expressed as mean ± S.E.M. (n = 10-12). Data were
statistically estimated using one-way ANOVA followed by Tukey’s multiple comparisons test. Variances were deemed statistically significant when *p < 0.05 in
contrast to the control group and @ p < 0.05 in contrast to D-gal treated group.
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Fig. 6. Effect of CQ on bone formation biomarkers in D-gal induced osteoporotic rats. Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.p.
for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with CQ (10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, serum BALP (a),
serum OCN (b), serum OPG (c), was established via the sandwich ELISA technique. Results are expressed as mean ± S.E.M. (n = 10-12). Data were statistically
estimated using one-way ANOVA followed by Tukey’s multiple comparisons test. Variances were deemed statistically significant when *p < 0.05 in contrast to the
control group and @ p < 0.05 in contrast to D-gal treated group.

2.9. Statistical analysis

3.2. Effect of CQ on serum calcium and phosphate in D-gal induced
osteoporotic rats

The statistical outcomes are obtainable as mean ± S.E.M. and were
factually investigated using one-way ANOVA followed by Tukey’s
multiple comparisons test. GraphPad Prism software version 6 (La Jolla,
CA, USA) was engaged for the statistical inquiry. Statistical significance
was set up as *p < 0.05 vs Normal control group, @ p < 0.05 vs D-gal
treated group.

D-gal treatment produced a significant rise in serum calcium and a
decline in serum phosphorus in D-gal treated group by 89 % and 32 %, in
respect to the control group. Treatment with CQ decreased serum cal
cium by 36 % while elevated serum phosphorus by 24 %, as compared to
D-gal treated group. Results are displayed in Fig. 4.

3. Results

3.3. Effect of CQ on anti-oxidant enzymes in D-gal induced osteoporotic
rats

3.1. Effect of CQ on bone mineral density in D-gal induced osteoporotic
rats

Both serum SOD and CAT showed a prominent decrease by about 31
% and 32 % respectively after being treated with D-gal for 8 successive
weeks regarding the control group as depicted in Fig. 5. A marked
elevation in serum SOD and CAT was observed after treatment with CQ
that succeeded to restore the anti-oxidant enzyme levels nonsignificant
from normal values.

The perusing and examination of bone engendered by DEXA showed
that D-gal produced reductions in tibia and femur BMD by around 45 %
and 37 % respectively regarded to the control group represented in
Fig. 3. The D-gal induced reductions in BMD of tibia and femur were
alleviated by oral CQ treatment and showed a marked elevation in tibia
and femur bone by about 40 % and 35 % respectively as regard to D-gal
treated group.

3.4. Effect of CQ on bone formation biomarkers in D-gal induced
osteoporotic rats
Results presented in Fig. 6 showed that
370
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Fig. 7. Effect of CQ on bone resorption biomarkers in D-gal induced osteoporotic rats. Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.
p. for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with CQ (10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, serum RANKL
(a), serum CTSK (b), and serum TRAP (c) were established via the sandwich ELISA technique. Results are expressed as mean ± S.E.M. (n = 10-12). Data were
statistically estimated using one-way ANOVA followed by Tukey’s multiple comparisons test. Variances were deemed statistically significant when *p < 0.05 in
contrast to the control group and @ p < 0.05 in contrast to D-gal treated group.

osteoporotic rats caused a marked upsurge in serum levels of (A) BALP
and (B) OCN by about 3 and 1folds respectively while hampered serum
(C) OPG by 36 % in respect to the control group. Treatment by CQ
blunted the elevation in serum levels of BALP and OCN by about 52 %
and 28 % respectively and replenished serum OPG in relation to D-gal
treated group.

Fig. 8. Osteoporotic group exhibited an elevation in ERK by about 1.2
folds as compared to the control group. Once more, treatment with CQ
turned off the increment and significantly mitigated ERK by 38 % in
respect to the D-gal treated group.

3.5. Effect of CQ on bone resorption biomarkers in D-gal induced
osteoporotic rats

Fig. 9 represents the photomicrograph of a longitudinal segment of
cancellous bone and represents the histological scoring report of the
osteoporotic bone. Bone tissue sequestered from D-gal treated group
exhibited irregularly sporadically disintegrated endosteal surface and
resorption cavities. Multinucleated osteoclasts with their acidic com
partments were also detected kept in the eroded bone surface. Moreover,
damage of the normal architecture of bone trabeculae with obvious
surge in the intertrabecular distance, which led to noticeable widening
of the interconnected bone marrow spaces, and apparent increment in
the adipocytes compared to (A) and (B) control group that has normal
bone structure. CQ treatment showed mild changes of micro
architectural of bone, appearance of osteocytes in trabecula bone along
with improvement of trabecular arrangement. However, signs of
resorption with micro-fissures were still obvious. The histopathological

3.7. Effect of CQ on histopathology in D-gal induced osteoporotic rats

D-gal induced osteoporotic rats augmented serum levels of (A)
RANKL, (B) CTSK, and (C) TRAP by 1.5, 2, and 2.5 folds after 8
consecutive weeks respectively in respect to the control group.
Conversely, treatment with CQ abrogated the elevated aforementioned
parameters in the order of the control group as demonstrated in Fig. 7

3.6. Effect of CQ on bone ERK protein kinase in D-gal induced
osteoporotic rats
ERK was measured in bone using western blot method to determine
its effect on the osteoclastogenesis in bone matrix as demonstrated in
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production of ROS that was indicated by the blunted antioxidant en
zymes SOD and CAT serum activity. These results are in harmony with
previous study of Muthusami et al. [50] in ovariectomized rats. On the
opposite side, CQ in the present study normalized the oxidoreductases
serum levels. Likewise, Iyawe et al. [51] reported the increase in anti
oxidant enzyme activity in plasmodium berghei infested mice treated
with CQ and ascorbic acid. The mechanism by which CQ restored the
antioxidant enzymes is still unclear however, it could be attributed to
the ability of CQ as a lysosomotropic agent to prevent osteoclastogenesis
[52].
Accelerated bone resorption via osteoclastic cells in osteoporotic rats
in the present work was illuminated by the increased serum level of
TRAP and CTSK; lysosomal proteases enzymes that are expressed in
osteoclast. The ruffled borders of osteoclast start degrading bone matrix
through the fusion of lysosomes with TRAP and CTSK [53]. It has been
reported that, deletion of in-vivo CTSK in osteoclastic cells resulted in
the activation of osteoblastic cells which in turn enhanced bone for
mation [54]. CQ as a lysosomotropic agent prohibited the acidification
of lysosome by neutralizing its pH thereby preventing TRAP and CTSK
activation and subsequently osteoclastogenesis [55].
Increased production of ROS following D-galactose treatment in the
current study resulted in a noticeable increase in bone ERK. Bhatt et al.
[56] reported that production of ROS stimulated ERK signaling which is
a very important pathway as it increases RANKL expression on osteo
blastic cells hence activating osteoclasts which in turn re-stimulate ROS
formation [57]. Likewise, in our study, sharp elevation in serum RANKL
together with a significant reduction in serum OPG thereby altered
RANKL/OPG ratio which indicated osteoclastogenesis [58]. Also,
upregulation of autophagy during oxidative stress contributes to dif
ferentiation of osteoclasts [59].
The osteo-protective effect of the CQ informed in the present study
was associated by lowering bone ERK. It has been reported that, CQ
hinder the activation of early members of the ERK signaling pathway
thus inhibiting RANKL expression and blocked the activation of different
inflammatory mediators [30] as illustrated in Fig. 10. CQ as
autophagy-lysosome inhibitor abrogated the autophagic flux thus pro
hibited osteoclast activation and subsequently the activation of ROS
[60]. Besides, CQ restored serum OPG which in turn increased expres
sion of OPG on osteoblastic cells and promotes bone formation. More
over, CTSK expression was found to be inhibited by normal levels of OPG
[61].

Fig. 8. Effect of CQ on femoral bone head expression of ERK protein kinase in
D-gal induced osteoporotic rats.
Osteoporosis was induced in male rats via injecting D-gal of 200 mg/kg/day, i.p.
for 8 consecutive weeks. Afterwards, osteoporotic rats were treated orally with
CQ (10 mg/kg) for 4 successive weeks. 24 h after the last dose of CQ, It was
determined using Western blot technique. Results are expressed as mean ± S.E.
M. (n = 10–12). Data were statistically estimated using one-way ANOVA fol
lowed by Tukey’s multiple comparisons test. Variances were deemed statisti
cally significant when *p < 0.05 in contrast to the control group and @ p < 0.05
in contrast to D-gal treated group.

scoring was according to [38] as shown in Table 1.
4. Discussion
Aged rat model has been established using D-gal which is a wellknown reducing sugar that deteriorates the biological conditions of
the cell as it imitates aging. It accumulates inside the cell at higher levels
and is reduced to galactitol that causes osmosis stress, swelling, and
subsequently ROS formation [39,40]. In the current study, D-galactose
induced bone loss was confirmed by marked decline in BMD of femur
and tibia. This was consistent with the findings of Djordjevic [41] and
El-Baz et al. [42] that showed a negative correlation between increase in
oxidative stress and BMD. The alterations in BMD assured osteoporosis
in D-galactose treated group compared to the control rats.
Marked increase in serum calcium levels together with the decline in
serum phosphate in the present study also established bone loss. This
could be attributed to the activation of OCs that leads to the infusion of
the extracellular fluid with calcium thus lowering the synthesis of 125
(OH)2D3 [43]. The further decline in serum 1,25 (OH)2D3 leads to the
reduction in the intestinal calcium and phosphate absorption [44,45].
Moreover, augmentation in serum OCN and BALP was observed which
could also contribute for the inhibition of calcium mineralization and to
the osteoclast break down of bone matrix according to [46,47].
Daily administration of osteoporotic male rats with CQ improved
BMD. It also mitigated serum calcium and subsequently raised serum
phosphate. Moreover, it showed a prominent reduction in serum OCN
and BALP. The mechanism could be accredited to the inhibition of OCs
which in turn elevated bone formation biomarkers; BALP and OCN that
resulted in calcium mineralization in bone matrix [48]. Also, the his
topathological examination revealed that, CQ had lessened the altered
bone structure compared to the osteoporotic control group. Notably, CQ
had no direct effect on bone formation biomarkers in bone marrow
stromal cells proposing that the main effect was on OCs [49].
Regular treatment of male rats with D-galactose increased the

5. Conclusion
The results of the present study revealed that in D-gal induced oste
oporosis; CQ showed valuable anti-osteoporotic effects which can be
attributed to its inhibitory effects on autophagy-lysosomal pathway thus
inhibiting osteoclast differentiation. Furthermore; CQ inhibited ERK
protein kinases activation with subsequent decrease in RANKL expres
sion on osteoblastic cells. This decline in RANKL results in an increase in
OPG which decreases TRAP and CTSK in the ruffled border of the OCs
thus preventing bone degradation.
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Fig. 9. Effect of CQ on Histopathological examination in D-gal induced osteoporotic rats. Section of (C) and (D) D-gal induced osteoporosis group shows revealed
irregularly sporadically disintegrated endosteal surface and resorption cavities, irregular thickness of the remaining trabeculae, osteoclasts with their acidic com
partments and multiple nuclei were detected kept in the eroded bone surface as well as an increment in bone marrow adipocytes compared to the (A) and (B) control
groups that showed regular histological structure. Section of (E) and (F) CQ treated group shows mild changes of microarchitectural of bone, trabecular continuity
shows some resorption micro-fissures and bony trabeculae enclosing osteocytes in their lacunae. The percentage of osteoporosis were valued by mean of 5 and
represented as mean ± S.E.M. Data were statistically estimated using one-way ANOVA followed by Tukey’s multiple comparisons test. Variances were deemed
statistically significant when *p < 0.05 in contrast to the control group and @ p < 0.05 in contrast to D-gal treated group.
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Table 1
Histopathological scoring of osteoporotic rats treated with CQ according to [38].
Parameters
% of Bone loss

Groups
Control

D-galactose

CQ

0 (< 5%)

2+ (50− 75 %)*

1+ (25− 50 %)*@

The histopathological sections were examined for osteoporosis in 2 different
fields. Data are expressed as median (min-max) and analyzed Kruskel-Wallis
followed by Dunn’s Multiple Comparison test. Variances were deemed statisti
cally significant when *p < 0.05 in contrast to the control group and @ p < 0.05
in contrast to D-gal treated group.
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Fig. 10. Diagram summarizing the different bases upon which CQ inhibits osteoclastogenesis.
ROS: reactive oxygen species, ERK: extracellular regulated kinase, OCs: osteoclasts, RANKL: receptor activator of nuclear factor-κβ ligand, OPG: osteoprotegrin,
TRAP: tartrate resistant acid phosphatase, CTSK: cathepsin K.
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the genotoxicity, cytotoxicity and antimalarial effect of sodium metavanadate po in
a Plasmodium yoelii yoelii infected murine model, Toxicol. Rep. 7 (2020).
[25] K.D. Rainsford, A.L. Parke, M. Clifford-Rashotte, W.F. Kean, Therapy and
pharmacological properties of hydroxychloroquine and chloroquine in treatment
of systemic lupus erythematosus, rheumatoid arthritis and related diseases,
Inflammopharmacology 23 (5) (2015) 231–269.
[26] R. Thome, S.C. Lopes, F.T. Costa, L. Verinaud, Chloroquine: modes of action of an
undervalued drug, Immunol. Lett. 153 (1-2) (2013) 50–57.
[27] A. Lesiak, J. Narbutt, J. Kobos, R. Kordek, A. Sysa-Jedrzejowska, M. Norval, et al.,
Systematic administration of chloroquine in discoid lupus erythematosus reduces

The authors declare no conflict of interest.
References
[1] J. Woo, T. Kwok, J. Leung, N. Tang, Dietary intake, blood pressure and
osteoporosis, J. Hum. Hypertens. 23 (7) (2009) 451–455.
[2] S. Khosla, B.L. Riggs, Pathophysiology of age-related bone loss and osteoporosis,
Endocrinol. Metab. Clin. North Am. 34 (4) (2005) 1015–1030, xi.
[3] P. Kouka, A. Priftis, D. Stagos, A. Angelis, P. Stathopoulos, N. Xinos, et al.,
Assessment of the antioxidant activity of an olive oil total polyphenolic fraction
and hydroxytyrosol from a Greek Olea europea variety in endothelial cells and
myoblasts, Int. J. Mol. Med. 40 (3) (2017) 703–712.
[4] A.J. Dirks, C. Leeuwenburgh, The role of apoptosis in age-related skeletal muscle
atrophy, Sport. Med. 35 (6) (2005) 473–483.
[5] S.S. Sabharwal, P.T. Schumacker, Mitochondrial ROS in cancer: initiators,
amplifiers or an Achilles’ heel? Nature reviews, Cancer 14 (11) (2014) 709–721.
[6] K.J. Gupta, A. Kumari, I. Florez-Sarasa, A.R. Fernie, A.U. Igamberdiev, Interaction
of nitric oxide with the components of the plant mitochondrial electron transport
chain, J. Exp. Bot. 69 (14) (2018) 3413–3424.
[7] T. Mitchell, B. Chacko, S.W. Ballinger, S.M. Bailey, J. Zhang, V. Darley-Usmar,
Convergent mechanisms for dysregulation of mitochondrial quality control in
metabolic disease: implications for mitochondrial therapeutics, Biochem. Soc.
Trans. 41 (1) (2013) 127–133.
[8] H. Nojiri, Y. Saita, D. Morikawa, K. Kobayashi, C. Tsuda, T. Miyazaki, et al.,
Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis
and impaired collagen cross-linking, J. Bone Miner. Res. 26 (11) (2011)
2682–2694.
[9] A. do Nascimento Cavalcante, L.K.F. Lima, C.M. Araujo, F.P. da Silva Santos, M.
O. do Nascimento, E.S.J.M. de Castro, et al., Toxicity, cytotoxicity, mutagenicity
and in vitro antioxidant models of 2-oleyl-1,3-dipalmitoyl-glycerol isolated from
the hexane extract of Platonia insignis MART seeds, Toxicol. Rep. 7 (2020)
209–216.
[10] V.O. Ikumawoyi, O. Awodele, E.O. Agbaje, C.G. Alimba, A.A. Bakare, O. Akinloye,
Bioactivity and modulatory functions of Napoleona vogelii on oxidative stressinduced micronuclei and apoptotic biomarkers in mice, Toxicol. Rep. 6 (2019)
963–974.
[11] I. Juranek, D. Nikitovic, D. Kouretas, A.W. Hayes, A.M. Tsatsakis, Biological
importance of reactive oxygen species in relation to difficulties of treating
pathologies involving oxidative stress by exogenous antioxidants, Food Chem.
Toxicol. 61 (2013) 240–247.

374

M.A.A. Mahmoud et al.

[28]
[29]
[30]
[31]

[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]

[43]

[44]

[45]

Toxicology Reports 8 (2021) 366–375
[46] K.K. Ivaska, T.A. Hentunen, J. Vaaraniemi, H. Ylipahkala, K. Pettersson, H.
K. Vaananen, Release of intact and fragmented osteocalcin molecules from bone
matrix during bone resorption in vitro, J. Biol. Chem. 279 (18) (2004)
18361–18369.
[47] S. Boulbaroud, A. Mesfioui, A. Arfaoui, A. Ouichou, A. el-Hessni, Preventive effects
of flaxseed and sesame oil on bone loss in ovariectomized rats, Pak. J. Biol. Sci.:
PJBS 11 (13) (2008) 1696–1701.
[48] M.L. Zoch, T.L. Clemens, R.C. Riddle, New insights into the biology of osteocalcin,
Bone 82 (2016) 42–49.
[49] Y. Xiu, H. Xu, C. Zhao, J. Li, Y. Morita, Z. Yao, et al., Chloroquine reduces
osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation,
J. Clin. Invest. 124 (1) (2014) 297–310.
[50] S. Muthusami, I. Ramachandran, B. Muthusamy, G. Vasudevan, V. Prabhu,
V. Subramaniam, et al., Ovariectomy induces oxidative stress and impairs bone
antioxidant system in adult rats, Clin. Chim. Acta 360 (1-2) (2005) 81–86.
[51] H. Iyawe, A.O O, O.O A, Effect of chloroquine and ascorbic acid interaction on the
oxidative stress status of Plasmodium berghei infested mice, Int. J. Pharmacol. 2
(2006).
[52] D.J. Klionsky, F.C. Abdalla, H. Abeliovich, R.T. Abraham, A. Acevedo-Arozena,
K. Adeli, et al., Guidelines for the use and interpretation of assays for monitoring
autophagy, Autophagy 8 (4) (2012) 445–544.
[53] L. Antika, Y.-H. Kim, M.-K. Kang, S.-H. Park, E.-J. Lee, Y.-J. Choi, et al., Dietary
compound gossypetin inhibits bone resorption through down-regulating lysosomal
cathepsin K activity and autophagy-related protein induction in actin ring-bearing
osteoclasts, J. Funct. Foods 24 (2016) 390–402.
[54] S. Lotinun, R. Kiviranta, T. Matsubara, J.A. Alzate, L. Neff, A. Luth, et al.,
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation,
J. Clin. Invest. 123 (2) (2013) 666–681.
[55] D.J. Rieman, H.A. McClung, R.A. Dodds, S.M. Hwang, M.W. Holmes, I.E. James, et
al., Biosynthesis and processing of cathepsin K in cultured human osteoclasts, Bone
28 (3) (2001) 282–289.
[56] N.Y. Bhatt, T.W. Kelley, V.V. Khramtsov, Y. Wang, G.K. Lam, T.L. Clanton, et al.,
Macrophage-colony-stimulating factor-induced activation of extracellularregulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen
species in human monocytes, J. Immunol. 169 (11) (2002) 6427–6434.
[57] T.S. Agidigbi, C. Kim, Reactive oxygen species in osteoclast differentiation and
possible pharmaceutical targets of ROS-Mediated osteoclast diseases, Int. J. Mol.
Sci. 20 (14) (2019).
[58] U.H. Lerner, New molecules in the tumor necrosis factor ligand and receptor
superfamilies with importance for physiological and pathological bone resorption,
Crit. Rev. Oral Biol. Med. 15 (2) (2004) 64–81.
[59] S. Liu, L. Zhu, J. Zhang, J. Yu, X. Cheng, B. Peng, Anti-osteoclastogenic activity of
isoliquiritigenin via inhibition of NF-kappaB-dependent autophagic pathway,
Biochem. Pharmacol. 106 (2016) 82–93.
[60] M. Redmann, G.A. Benavides, T.F. Berryhill, W.Y. Wani, X. Ouyang, M.S. Johnson,
et al., Inhibition of autophagy with bafilomycin and chloroquine decreases
mitochondrial quality and bioenergetic function in primary neurons, Redox Biol.
11 (2017) 73–81.
[61] M. Skoumal, G. Haberhauer, G. Kolarz, G. Hawa, W. Woloszczuk, A. Klingler,
Serum cathepsin K levels of patients with longstanding rheumatoid arthritis:
correlation with radiological destruction, Arthritis Res. Ther. 7 (1) (2005) R65–70.

skin lesions via inhibition of angiogenesis, Clin. Exp. Dermatol. 34 (5) (2009)
570–575.
Y. Yan, Z. Zou, Y. Sun, X. Li, K.F. Xu, Y. Wei, et al., Anti-malaria drug chloroquine
is highly effective in treating avian influenza A H5N1 virus infection in an animal
model, Cell Res. 23 (2) (2013) 300–302.
M. Mauthe, I. Orhon, C. Rocchi, X. Zhou, M. Luhr, K.J. Hijlkema, et al.,
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome
fusion, Autophagy 14 (8) (2018) 1435–1455.
S.M. Weber, J.M. Chen, S.M. Levitz, Inhibition of mitogen-activated protein kinase
signaling by chloroquine, J. Immunol. 168 (10) (2002) 5303–5309.
A. Seif, N. Fawzy, S. Abdelrahman, M. Emara, H. Zaki, M. Khattab, Stimulation of
ACE2/ANG(1–7)/Mas Axis by diminazene ameliorates alzheimer’s disease in the
D-Galactose-Ovariectomized rat model: role of PI3K/Akt pathway, Mol. Neurobiol.
55 (2018).
A.O. Adeeko, O.A. Dada, Chloroquine reduces fertilizing capacity of epididyma
sperm in rats, Afr. J. Med. Med. Sci. 27 (1-2) (1998) 63–64.
V. Somsak, A. Damkaew, P. Onrak, Antimalarial activity of Kaempferol and its
combination with chloroquine in Plasmodium berghei infection in mice, J. Pathog.
(2018), 3912090, 2018.
E.M. Gindler, J.D. King, Rapid colorimetric determination of calcium in biologic
fluids with methylthymol blue, Am. J. Clin. Pathol. 58 (4) (1972) 376–382.
M.M. El-Merzabani, A. Anwer-El-Aaser, N.I. Zakhary, A new method for
determination of inorganic phosphorus in serum without deproteinization, J. Clin.
Chem. Clin. Biochem. 15 (12) (1977) 715–718.
H. Aebi, Catalase in vitro, Meth. Enzymol. 105 (1984) 121–126.
N.A. Rao, M. Nishikimi, K. Yagi, Reactivity of D-amino acid oxidase with artificial
electron acceptors, Biochimica et biophysica acta 276 (2) (1972) 350–362.
U.M. Aswar, V. Mohan, S.L. Bodhankar, Antiosteoporotic activity of phytoestrogenrich fraction separated from ethanol extract of aerial parts of Cissus quadrangularis
in ovariectomized rats, Indian J. Pharmacol. 44 (3) (2012) 345–350.
N. Hadzi-Petrushev, V. Stojkovski, D. Mitrov, M. Mladenov, D-galactose induced
changes in enzymatic antioxidant status in rats of different ages, Physiol. Res. 64
(1) (2015) 61–70.
H. Jeong, Y. Liu, H.S. Kim, Dried plum and chokeberry ameliorate d-galactoseinduced aging in mice by regulation of Pl3k/Akt-mediated Nrf2 and Nf-kB
pathways, Exp. Gerontol. 95 (2017) 16–25.
V.B. Djordjevic, Free radicals in cell biology, Int. Rev. Cytol. 237 (2004) 57–89.
F.K. El-Baz, D.O. Saleh, G.A. Abdel Jaleel, R.A. Hussein, A. Hassan, Heamatococcus
pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via
the regulation of OPG/RANKL pathway, Biomed. Pharmacother. 116 (2019),
109017.
Y.L. Ma, R.L. Cain, D.L. Halladay, X. Yang, Q. Zeng, R.R. Miles, et al., Catabolic
effects of continuous human PTH (1–38) in vivo is associated with sustained
stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone
formation, Endocrinology 142 (9) (2001) 4047–4054.
N. Danilovich, P.S. Babu, W. Xing, M. Gerdes, H. Krishnamurthy, M.R. Sairam,
Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating
hormone receptor knockout (FORKO) female mice, Endocrinology 141 (11) (2000)
4295–4308.
R.P. Heaney, Toward a physiological referent for the vitamin D requirement,
J. Endocrinol. Invest. 37 (11) (2014) 1127–1130.

375

